OPTIMIZING GLOBAL CLINICAL TRIALS.

SEC. 569A. [21 U.S.C. 360bbb–8a] OPTIMIZING GLOBAL CLINICAL TRIALS. (a) In General.—The Secretary shall— (1) work with other regulatory authorities of similar standing, medical research companies, and international organizations to foster and encourage uniform, scientifically driven clinical trial standards with respect to medical products around the world; and (2) enhance the commitment to provide consistent parallel scientific advice to manufacturers seeking simultaneous global development of new medical products in order to— (A) enhance medical product development; (B) facilitate the use of foreign data; and (C) minimize the need to conduct duplicative clinical studies, preclinical studies, or nonclinical studies. (b) Medical Product.—In this section, the term “medical product” means a drug, as defined in subsection (g) of section 201, a device, as defined in subsection (h) of such section, or a biological product, as defined in section 351(i) of the Public Health Service Act. (c) Savings Clause.—Nothing in this section shall alter the criteria for evaluating the safety or effectiveness of a medical product under this Act or under the Public Health Service Act.